Your browser doesn't support javascript.
loading
A Dutch nationwide evaluation of serological assays for detection of Borrelia antibodies in clinically well-defined patients.
Ang, C W; Brandenburg, A H; van Burgel, N D; Bijlmer, H A; Herremans, T; Stelma, F; Lunel, F Verduyn; van Dam, A P.
Afiliación
  • Ang CW; Department of Medical Microbiology and Infection Control, VU University Medical Centre, Amsterdam, The Netherlands. Electronic address: w.ang@vumc.nl.
  • Brandenburg AH; Center for Infectious Diseases, Izore, Leeuwarden, The Netherlands.
  • van Burgel ND; Department of Medical Microbiology, Centre of Infectious Diseases, Leiden University Medical Centre, Leiden, The Netherlands.
  • Bijlmer HA; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
  • Herremans T; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands.
  • Stelma F; Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Lunel FV; Department of Medical Microbiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • van Dam AP; OLVG/Public Health Laboratory, Amsterdam, The Netherlands.
Diagn Microbiol Infect Dis ; 83(3): 222-8, 2015 Nov.
Article en En | MEDLINE | ID: mdl-26286381
Numerous tests for the detection of antibodies against Borrelia burgdorferi are commercially available. Manufacturer-derived data invariably report a high sensitivity and specificity, but comparative studies demonstrate large differences in clinical practice, especially with regard to specificity. We retrospectively collected data from validation studies for B. burgdorferi antibody assays from 8 laboratories in the Netherlands. The total number of samples was 809. Samples were selected based on clinical and laboratory parameters. We included samples from patients with erythema migrans, acrodermatitis chronicum atrophicans, and neuroborreliosis; cross-reactivity controls; and healthy controls. Data are presented from 10 enzyme-linked immunosorbent assays and 5 immunoblots. For manifestations of B. burgdorferi infection with short disease duration, the positivity rate of the assays varied significantly. In patients with long disease duration, the positivity rate differed only marginally. In cross-reactivity controls, there was significant variation in the reactivity rate. The majority of false-positive reactions are of the IgM isotype.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Lyme / Pruebas Serológicas / Borrelia burgdorferi / Anticuerpos Antibacterianos Tipo de estudio: Diagnostic_studies / Evaluation_studies / Observational_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Diagn Microbiol Infect Dis Año: 2015 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Lyme / Pruebas Serológicas / Borrelia burgdorferi / Anticuerpos Antibacterianos Tipo de estudio: Diagnostic_studies / Evaluation_studies / Observational_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Diagn Microbiol Infect Dis Año: 2015 Tipo del documento: Article Pais de publicación: Estados Unidos